Business Description
NervGen Pharma Corp
NAICS : 325412
SIC : 3741
ISIN : CA64082X2032
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 58.89 | |||||
Equity-to-Asset | -0.15 | |||||
Debt-to-Equity | -0.1 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -2.6 | |||||
3-Year EPS without NRI Growth Rate | 5.8 | |||||
3-Year FCF Growth Rate | 0.5 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 41.75 | |||||
9-Day RSI | 40.93 | |||||
14-Day RSI | 39.32 | |||||
6-1 Month Momentum % | 15 | |||||
12-1 Month Momentum % | 38.79 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.83 | |||||
Quick Ratio | 0.83 | |||||
Cash Ratio | 0.77 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19.2 | |||||
Shareholder Yield % | 0.05 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -329.18 | |||||
ROA % | -124.37 | |||||
ROIC % | -201.06 | |||||
ROC (Joel Greenblatt) % | -9075.36 | |||||
ROCE % | -322.23 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -5.84 | |||||
EV-to-EBITDA | -5.87 | |||||
EV-to-FCF | -12.05 | |||||
Earnings Yield (Greenblatt) % | -17.12 | |||||
FCF Yield % | -7.82 |